Knoll Capital Management’s Elicio Therapeutics ELTX Stock Holding History

Knoll Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.74M	Hold	630,915	–	–	3.74%	11
2025 Q4	$5.02M	Hold	630,915	–	–	2.3%	18
2025 Q3	$6.9M	Hold	630,915	–	–	3.7%	12
2025 Q2	$4.87M	Hold	630,915	–	–	3.46%	10
2025 Q1	$3.89M	Buy	+630,915	New	+$4.89M	2.53%	13
2022 Q3	–	Sell	-6,000	Closed	-$68K	–	37
2022 Q2	$68K	Hold	6,000	–	–	0.04%	40
2022 Q1	$127K	Hold	6,000	–	–	0.08%	40
2021 Q4	$174K	Hold	6,000	–	–	0.1%	38
2021 Q3	$586K	Hold	6,000	–	–	0.29%	26
2021 Q2	$781K	Hold	6,000	–	–	0.41%	28
2021 Q1	$1.08M	Buy	+6,000	New	+$1.16M	0.71%	20

Other funds holding ELTX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Knoll Capital Management's ELTX Position: Q1 2026 in Review

Knoll Capital Management held its Elicio Therapeutics (ELTX) position steady in Q1 2026 at 630,915 shares worth $6.74M. The position accounts for 3.74% of the portfolio, ranked #11.

Knoll Capital Management first reported a position in ELTX in Q1 2021 and has held it in 11 quarters since. The position peaked at $6.9M in Q3 2025. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

Knoll Capital Management held 630,915 shares of Elicio Therapeutics worth $6.74M as of Q1 2026.
Knoll Capital Management left its Elicio Therapeutics share count unchanged in Q1 2026.
Elicio Therapeutics made up 3.74% of Knoll Capital Management's portfolio in Q1 2026, its #11 holding.
Knoll Capital Management first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 11 quarters since.
Knoll Capital Management's Elicio Therapeutics position peaked at $6.9M in Q3 2025.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Knoll Capital Management's 13F filing for Q1 2026, filed 15 May 2026.